Amylyx Pharmaceuticals, Inc.

AMLX · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Assets
Cash & Equivalents$77,391$170,201$62,526$50,191
Short-Term Investments$99,110$201,161$284,419$45,927
Receivables$447$40,050$15,306$0
Inventory$0$38,323$9,769$0
Other Curr. Assets$12,484$14,931$10,113$8,833
Total Curr. Assets$189,432$464,666$382,133$104,951
Property Plant & Equip (Net)$2,732$6,411$8,135$474
Goodwill$0$0$0$0
Intangibles$0$0$0$0
Long-Term Investments$0$0$0$0
Tax Assets$0$0$0$0
Other NC Assets$1,470$46,377$1,185$189
Total NC Assets$4,202$52,788$9,320$663
Other Assets$0$0$0$0
Total Assets$193,634$517,454$391,453$105,614
Liabilities
Payables$2,939$22,061$6,257$4,372
Short-Term Debt$1,518$2,257$2,040$0
Tax Payable$0$0$0$0
Deferred Revenue$0$0$0$0
Other Curr. Liab.$23,949$57,724$38,312$13,024
Total Curr. Liab.$28,406$82,042$46,609$17,396
LT Debt$463$1,980$4,237$0
Deferred Rev, NC$0$0$0$0
Deferred Tax Liab, NC$0$0$0$0
Other NC Liab.$0$0$0$239,386
Total NC Liab.$463$1,980$4,237$239,386
Other Liabilities$0$0$0$0
Cap. Leases$1,981$4,237$6,277$0
Total Liabilities$28,869$84,022$50,846$256,782
Equity
Pref Stock$0$0$0$0
Common Stock$7$7$7$1
Retained Earnings-$606,692-$304,949-$354,220-$155,845
AOCI-$92$197-$86$9
Other Equity$771,542$738,177$694,906$4,667
Total Equity$164,765$433,432$340,607-$151,168
Supplemental Information
Minority Interest$0$0$0$0
Total Liab. & Tot. Equity$193,634$517,454$391,453$105,614
Net Debt-$75,410-$165,964-$56,249-$50,191